174 related articles for article (PubMed ID: 29253744)
1. Severe neutropenia after rituximab-treatment of multiple sclerosis.
Rissanen E; Remes K; Airas L
Mult Scler Relat Disord; 2018 Feb; 20():3-5. PubMed ID: 29253744
[TBL] [Abstract][Full Text] [Related]
2. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
3. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hospitalization due to infection in rituximab-treated MS patients.
Karlowicz JR; Klakegg M; Aarseth JH; Bø L; Myhr KM; Torgauten HM; Torkildsen Ø; Wergeland S
Mult Scler Relat Disord; 2023 Mar; 71():104556. PubMed ID: 36842313
[TBL] [Abstract][Full Text] [Related]
5. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review.
Shahmohammadi S; Sahraian MA; Shahmohammadi A; Doosti R; Zare-Mirzaie A; Naser Moghadasi A
Mult Scler Relat Disord; 2018 May; 22():22-26. PubMed ID: 29524758
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
8. Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.
Marrodan M; Laviano J; Oneto S; Reino FM; Delorme R; Fornillo F; Férnandez J; Correale J
Neurol Sci; 2021 Sep; 42(9):3893-3895. PubMed ID: 34075515
[No Abstract] [Full Text] [Related]
9. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.
McKay KA; Piehl F; Englund S; He A; Langer-Gould A; Hillert J; Frisell T
JAMA Netw Open; 2021 Dec; 4(12):e2136697. PubMed ID: 34851401
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
Mealy MA; Levy M
J Neuroimmunol; 2015 Oct; 287():29-30. PubMed ID: 26439958
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced serum sickness in multiple sclerosis patients.
Wolf AB; Ryerson LZ; Pandey K; McGettigan BM; Vollmer T; Corboy JR; Alvarez E
Mult Scler Relat Disord; 2019 Nov; 36():101402. PubMed ID: 31542710
[TBL] [Abstract][Full Text] [Related]
13. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.
Reitblat T; Wechsler A; Reitblat O
Am J Case Rep; 2015 Apr; 16():211-4. PubMed ID: 25855510
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
16. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment for multiple sclerosis.
Ineichen BV; Moridi T; Granberg T; Piehl F
Mult Scler; 2020 Feb; 26(2):137-152. PubMed ID: 31237800
[TBL] [Abstract][Full Text] [Related]
19. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
Berntsson SG; Kristoffersson A; Boström I; Feresiadou A; Burman J; Landtblom AM
Acta Neurol Scand; 2018 Oct; 138(4):327-331. PubMed ID: 29797711
[TBL] [Abstract][Full Text] [Related]
20. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Maillart E; Lippi A; Lubetzki C; Louapre C; Papeix C
Mult Scler Relat Disord; 2018 Feb; 20():220-222. PubMed ID: 29433095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
